# A Study of Imatinib and Docetaxel in Prostate Cancer

> **NCT00251225** · PHASE2 · COMPLETED · sponsor: **Leonard Appleman** · enrollment: 49 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Gleevec
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00251225
- **Lead sponsor:** Leonard Appleman
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-03
- **Final completion:** 2014-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00251225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00251225, "A Study of Imatinib and Docetaxel in Prostate Cancer". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00251225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*